Premium
Partial thickness Macular holes and pharmaceutical treatment of FTMH
Author(s) -
Pournaras J.A.
Publication year - 2017
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2017.02712
Subject(s) - macular hole , vitrectomy , ophthalmology , medicine , epiretinal membrane , optometry , visual acuity
Summary The pathophysiology of full thickness macular hole and lamellar macular hole aredifferent and will be discussed. Oct characteristics will be repeated according to newclassification. Taking in account the natural history, indication of treatment will bedetailled according to each stage of those diseases. Recently, ocriplasmin has beenintroduced as an alternative treatment to vitrectomy. Favorable Prognostic factorshave been recognized as age inferior to 65 years old, full thickness macular hole < 400microns, the absence of epiretinal membrane, vitreous adhesion < 1500 microns andphakic status. While management of full thickness macular hole shows good visualprognosis for the patients, the visual result of lamelar macular hole is not so obvious.